# A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

> **NCT00668148** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 113 (actual)

## Conditions studied

- Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET)
- Rhabdomyosarcoma
- Leiomyosarcoma
- Adipocytic Sarcoma
- Synovial Sarcoma

## Interventions

- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** IMC-A12 (cixutumumab)

## Key facts

- **NCT ID:** NCT00668148
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-10
- **Final completion:** 2012-02
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668148, "A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00668148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*